Biotech · Public company · Durham, NC, US

Opus Genetics, Inc.

Ticker IRD · SEC CIK 0001228627

Track this companyFree. Adds Opus Genetics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials174 recruiting or active

Pipeline programs20From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline20

0.75% phentolamine ophthalmic solutionPhase 3 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
0.75% Phentolamine Ophthalmic SolutionPhase 3 · Vision Loss NightClinicalTrials.gov · fetched Nov 12, 2026
Low dose pilocarpinePhase 3 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
Low dose pilocarpine vehiclePhase 3 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Ophthalmic Solution 0.75%Phase 3 · MydriasisClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Ophthalmic Solution 0.75%Phase 3 · Dim Light Vision DisturbancesClinicalTrials.gov · fetched Nov 12, 2026
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonistPhase 3 · Mesopic VisionClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Ophthalmic Solution VehiclePhase 3 · MydriasisClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Opthalmic Solution 0.75%Phase 3 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
AAV8.hLCA5Phase 2 · LCA5ClinicalTrials.gov · fetched Nov 12, 2026
APX3330Phase 2 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
OPGx-BEST1Phase 2 · ARBClinicalTrials.gov · fetched Nov 12, 2026
OPGx-RDH12Phase 2 · Leber Congenital AmaurosisClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Mesylate Ophthalmic Solution 0.5%Phase 2 · Night Vision ComplaintsClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Mesylate Ophthalmic Solution 1.0%Phase 2 · Night Vision ComplaintsClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Mesylate Ophthalmic Solution 1%Phase 2 · Decrease in Night VisionClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Mesylate Ophthalmic Solution 1%Phase 2 · MydriasisClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Mesylate Ophthalmic Solution 1%Phase 2 · Open Angle GlaucomaClinicalTrials.gov · fetched Nov 12, 2026
Phentolamine Ophthalmic Solution 0.75%Phase 2 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026
PilocarpinePhase 2 · PresbyopiaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials17

Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)PHASE1_PHASE2 · RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07681778 · fetched Nov 12, 2026
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)PHASE1_PHASE2 · RECRUITING · started Sep 25, 2025ClinicalTrials.gov NCT07185256 · fetched Nov 12, 2026
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual AcuityPHASE3 · RECRUITING · started Sep 2, 2025ClinicalTrials.gov NCT07140783 · fetched Nov 12, 2026
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaPHASE3 · COMPLETED · started Aug 15, 2024ClinicalTrials.gov NCT06542497 · fetched Nov 12, 2026
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesPHASE3 · COMPLETED · started Apr 1, 2024ClinicalTrials.gov NCT06349759 · fetched Nov 12, 2026
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated PatientsPHASE1_PHASE2 · RECRUITING · started Jun 15, 2023ClinicalTrials.gov NCT05616793 · fetched Nov 12, 2026
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPHASE3 · COMPLETED · started Dec 22, 2022ClinicalTrials.gov NCT05646719 · fetched Nov 12, 2026
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric SubjectsPHASE3 · COMPLETED · started Dec 17, 2021ClinicalTrials.gov NCT05223478 · fetched Nov 12, 2026
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)PHASE3 · COMPLETED · started Nov 18, 2021ClinicalTrials.gov NCT05134974 · fetched Nov 12, 2026
Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyPHASE2 · COMPLETED · started Apr 8, 2021ClinicalTrials.gov NCT04692688 · fetched Nov 12, 2026
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With PresbyopiaPHASE2 · COMPLETED · started Feb 15, 2021ClinicalTrials.gov NCT04675151 · fetched Nov 12, 2026
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision DisturbancesPHASE3 · COMPLETED · started Dec 30, 2020ClinicalTrials.gov NCT04638660 · fetched Nov 12, 2026
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced MydriasisPHASE3 · COMPLETED · started Nov 18, 2020ClinicalTrials.gov NCT04620213 · fetched Nov 12, 2026
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced MydriasisPHASE2 · COMPLETED · started Aug 13, 2019ClinicalTrials.gov NCT04024891 · fetched Nov 12, 2026
Safety and Efficacy of Ophthalmic Phentolamine Mesylate in GlaucomaPHASE2 · COMPLETED · started May 28, 2019ClinicalTrials.gov NCT03960866 · fetched Nov 12, 2026
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision DisturbancesPHASE2 · COMPLETED · started Sep 9, 2011ClinicalTrials.gov NCT01703559 · fetched Nov 12, 2026
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision DisturbancesPHASE2 · COMPLETED · started Aug 1, 2007ClinicalTrials.gov NCT04004507 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 21, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 9, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026

NIH awards4

Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.Fiscal year 2026 · $1MNIH RePORTER 1R44EY038149-01A1 · fetched Nov 12, 2026
Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA)Fiscal year 2026 · $1MNIH RePORTER 1R44EY038152-01A1 · fetched Nov 12, 2026
A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa.Fiscal year 2025 · $836.9KNIH RePORTER 5R44EY036301-02 · fetched Nov 12, 2026
A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa.Fiscal year 2024 · $883KNIH RePORTER 1R44EY036301-01 · fetched Nov 12, 2026